A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

CompletedOBSERVATIONAL

Enrollment

111

Participants

Timeline

Start Date

July 23, 2018

Primary Completion Date

February 13, 2023

Study Completion Date

February 13, 2023

Conditions

Anaplastic Lymphoma Kinase-positiveCarcinoma Non-small-cell Lung

Interventions

DRUG

Brigatinib

Brigatinib tablets.

DRUG

Alectinib

Alectinib capsules.

DRUG

Ceritinib

Ceritinib capsules.

DRUG

Lorlatinib

Lorlatinib capsules.

DRUG

Any FDA Approved ALK Inhibitors

FDA approved ALK inhibitors available for treatment.

Trial Locations (1)

EmpiraMed, Inc., Maynard